YAP1 and its fusion proteins in cancer initiation, progression and therapeutic resistance

被引:88
|
作者
Szulzewsky, Frank [1 ]
Holland, Eric C. [1 ,2 ]
Vasioukhin, Valeri [1 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Human Biol Div, Seattle, WA 98109 USA
[2] Fred Hutchinson Canc Res Ctr, Seattle Tumor Translat Res Ctr, Seattle, WA 98109 USA
关键词
YAP1; Gene fusions; fusion; Cancer; Hippo signaling pathway; YES-ASSOCIATED PROTEIN; HIPPO SIGNALING-PATHWAY; TUMOR-SUPPRESSOR PATHWAY; GENOME-WIDE ASSOCIATION; ORGAN SIZE CONTROL; CELL-PROLIFERATION; TRANSCRIPTIONAL COACTIVATOR; NUCLEAR-LOCALIZATION; UVEAL MELANOMA; TISSUE-GROWTH;
D O I
10.1016/j.ydbio.2020.12.018
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
YAP1 is a transcriptional co-activator whose activity is controlled by the Hippo signaling pathway. In addition to important functions in normal tissue homeostasis and regeneration, YAP1 has also prominent functions in cancer initiation, aggressiveness, metastasis, and therapy resistance. In this review we are discussing the molecular functions of YAP1 and its roles in cancer, with a focus on the different mechanisms of de-regulation of YAP1 activity in human cancers, including inactivation of upstream Hippo pathway tumor suppressors, regulation by intersecting pathways, miRNAs, and viral oncogenes. We are also discussing new findings on the function and biology of the recently identified family of YAP1 gene fusions, that constitute a new type of activating mutation of YAP1 and that are the likely oncogenic drivers in several subtypes of human cancers. Lastly, we also discuss different strategies of therapeutic inhibition of YAP1 functions.
引用
收藏
页码:205 / 221
页数:17
相关论文
共 50 条
  • [31] YAP1 fusion proteins mediate oncogenic activity in ependymoma via interaction with TEAD transcription factors
    Pajtler, Kristian W.
    Okonechnikov, Konstantin
    Vouri, Mikaella
    Brabetz, Sebastian
    Jones, David T.
    Korshunov, Andrey
    Capper, David
    Chavez, Lukas
    Pfister, Stefan M.
    Kool, Marcel
    Kawauchi, Daisuke
    CANCER RESEARCH, 2018, 78 (13)
  • [32] Therapeutic co-targeting YAP1 and TAZ using antisense oligos (ASOs) suppress gastric cancer progression and peritoneal metastases
    Wu, Jingjing
    Scott, Ailing
    Xu, Yan
    Li, Yuan
    Fan, Yibo
    Wang, Ruiping
    Yao, Xiaodan
    Yoshimura, Katsuhiro
    Pizzi, Melissa Pool
    Yamashita, Kohei
    Shao, Shan
    Vellano, Christopher
    Wang, Linghua
    Revenko, Alexey
    Dolinski, Eric
    Ajani, Jaffer A.
    Song, Shumei
    CANCER RESEARCH, 2023, 83 (07)
  • [33] Correction: Inhibition of the AURKA/YAP1 axis is a promising therapeutic option for overcoming cetuximab resistance in colorectal cancer stem cells
    Anxo Rio-Vilariño
    Aiora Cenigaonandia-Campillo
    Ana García-Bautista
    Pedro A. Mateos-Gómez
    Marina I. Schlaepfer
    Laura del Puerto-Nevado
    Oscar Aguilera
    Laura García-García
    Carlos Galeano
    Irene de Miguel
    Juana Serrano-López
    Natalia Baños
    María Jesús Fernández-Aceñero
    Juan Carlos Lacal
    Enzo Medico
    Jesús García-Foncillas
    Arancha Cebrián
    British Journal of Cancer, 2024, 130 : 1414 - 1414
  • [34] CircSETD2 inhibits YAP1 by interaction with HuR during breast cancer progression
    Lan, Jing
    Liu, Yang
    Cao, Jianbo
    Wan, Yuqiu
    Zhou, Yehui
    CANCER BIOLOGY & THERAPY, 2023, 24 (01)
  • [35] DLAT promotes triple-negative breast cancer progression via YAP1 activation
    Liu, Diya
    Wang, Xuehui
    Qian, Fengyuan
    Ye, Danrong
    Deng, Xiaochong
    Fang, Lin
    CANCER BIOLOGY & THERAPY, 2024, 25 (01)
  • [36] Tumor-selective proteotoxicity of verteporfin inhibits colon cancer progression independently of YAP1
    Zhang, Huabing
    Ramakrishnan, Sadeesh K.
    Triner, Daniel
    Centofanti, Brook
    Maitra, Dhiman
    Gyorffy, Balazs
    Sebolt-Leopold, Judith S.
    Dame, Michael K.
    Varani, James
    Brenner, Dean E.
    Fearon, Eric R.
    Omary, M. Bishr
    Shah, Yatrik M.
    SCIENCE SIGNALING, 2015, 8 (397)
  • [37] CAFs activated by YAP1 upregulate cancer matrix stiffness to mediate hepatocellular carcinoma progression
    Wei Yan
    Guo-hui Xiao
    Li-juan Wang
    Yan Zhou
    Fa Yang
    Kuan-hou Mou
    Journal of Translational Medicine, 23 (1)
  • [38] Sustained Adrenergic Activation of YAP1 Induces Anoikis Resistance in Cervical Cancer Cells
    Li, Yang
    Yang, Shanshan
    Sadaoui, Nouara C.
    Hu, Wei
    Dasari, Santosh K.
    Mangala, Lingegowda S.
    Sun, Yunjie
    Zhao, Shuangtao
    Wang, Linghua
    Liu, Yuan
    Ramondetta, Lois M.
    Li, Ke
    Lu, Chong
    Kang, Yu
    Cole, Steve W.
    Lutgendorf, Susan K.
    Sood, Anil K.
    ISCIENCE, 2020, 23 (07)
  • [39] KAT7 promoted gastric cancer progression through promoting YAP1 activation
    Guo, Xueyan
    Li, Yulong
    Wan, Bingbing
    Lv, Yifei
    Wang, Xue
    Liu, Guisheng
    Wang, Ping
    PATHOLOGY RESEARCH AND PRACTICE, 2022, 237
  • [40] Increased YAP1 expression is significantly associated with breast cancer progression, metastasis and poor survival
    Qadir, Javeria
    Riaz, Syeda Kiran
    Taj, Kiran
    Sattar, Natasha
    Sahar, Namood-e
    Khan, Jahangir Sarwar
    Kayani, Mahmood Akhtar
    Haq, Farhan
    Arshad Malik, Muhammad Faraz
    FUTURE ONCOLOGY, 2021, 17 (21) : 2725 - 2734